Plain-English translation of NCT07116915 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our COPD research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial examined the safety and tolerability of HRS-9821, a medication inhaled directly into the lungs. Researchers tested the medication in two groups: healthy people who received a single dose, and patients with COPD who received the medication daily for 12 days. The study aimed to understand how the medication worked in the body and whether it caused any unwanted side effects.
COPD is a chronic lung disease that makes breathing difficult, and current treatments don't work well enough for everyone. This trial was designed to evaluate whether this new treatment could be a safe option to help people breathe better.
Healthy volunteers came to the study site and inhaled a single dose of the medication or a placebo (inactive treatment), then were monitored for safety. Patients with COPD inhaled the medication or placebo daily for 12 consecutive days while researchers checked their heart rhythm, lung function, and blood work at regular visits. Participants in both groups also kept track of any side effects they experienced throughout the trial.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
China